About silence therapeutics - SLNCF
Silence Therapeutics Plc engages in the discovery, delivery, and development of ribonucleic acid (RNA) therapeutics. It also develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.
SLNCF At a Glance
Silence Therapeutics Plc
12 Hammersmith Grove
London, Greater London W6 7AP
| Phone | 44-20-3457-6900 | Revenue | 43.26M | |
| Industry | Miscellaneous Commercial Services | Net Income | -45,309,000.00 | |
| Sector | Commercial Services | 2024 Sales Growth | 37.142% | |
| Fiscal Year-end | 12 / 2025 | Employees | 116 | |
| View SEC Filings |
SLNCF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 8.42 |
| Price to Book Ratio | 2.775 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.43 |
| Enterprise Value to Sales | 5.017 |
| Total Debt to Enterprise Value | 0.001 |
SLNCF Efficiency
| Revenue/Employee | 372,913.793 |
| Income Per Employee | -390,594.828 |
| Receivables Turnover | 1.608 |
| Total Asset Turnover | 0.268 |
SLNCF Liquidity
| Current Ratio | 11.138 |
| Quick Ratio | 11.138 |
| Cash Ratio | 8.758 |
SLNCF Profitability
| Gross Margin | 72.105 |
| Operating Margin | -114.619 |
| Pretax Margin | -102.788 |
| Net Margin | -104.741 |
| Return on Assets | -28.121 |
| Return on Equity | -58.179 |
| Return on Total Capital | -33.777 |
| Return on Invested Capital | -58.134 |
SLNCF Capital Structure
| Total Debt to Total Equity | 0.087 |
| Total Debt to Total Capital | 0.087 |
| Total Debt to Total Assets | 0.058 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |